GABAergic system in the endocrine pancreas: a new target for diabetes treatment
Yun Wan,1 Qinghua Wang,1–3 Gerald J Prud’homme4,5 1Department of Endocrinology and Metabolism, Huashan Hospital, Medical College, Fudan University, Shanghai, People’s Republic of China; 2Division of Endocrinology and Metabolism, Keenan Research Centre for Biomedical Sc...
Guardado en:
Autores principales: | Wan Y, Wang Q, Prud’homme GJ |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/4774e9c51e6f42f792c35670dd15e233 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Prolylcarboxypeptidase (PRCP) as a new target for obesity treatment
por: B Shariat-Madar, et al.
Publicado: (2010) -
Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus
por: Whaley JM, et al.
Publicado: (2012) -
Effect of different exercise intensities on the pancreas of animals with metabolic syndrome
por: Amaral F, et al.
Publicado: (2015) -
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Baptist Gallwitz
Publicado: (2010) -
Treatment of type 2 diabetes in chronic kidney disease: a case for linagliptin in the treatment of diabetes in severe renal impairment
por: Scott D
Publicado: (2013)